Michael Davis
Upcoming SlideShare
Loading in...5
×
 

Michael Davis

on

  • 443 views

 

Statistics

Views

Total Views
443
Views on SlideShare
443
Embed Views
0

Actions

Likes
0
Downloads
5
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Michael Davis Michael Davis Presentation Transcript

  • Value through Innovation ABCD
  • Value Through Innovation
    • Boehringer Ingelheim is committed to becoming the most innovative research, development and distribution enterprise in the world, providing products that significantly enhance health and quality of life.
      • Currently investigating therapies for over 22 acute and chronic conditions that drive up US health care costs.
      • 17% net sales to R&D
  • BI Worldwide
    • Family owned – Boehringer
    • Founded in Ingelheim / Germany in 1885
    • Operating worldwide
        • 156 affiliates in over 60 countries
        • 35,700 employees
    • Focus on Human Pharmaceuticals – 95%
        • Prescription medicines – Brand and Generic
        • Over-the-Counter medicines
  • Pharmaceutical R&D BIPKG (Karl Thomae) Boehringer Ingelheim Pharmaceuticals BI Austria Boehringer Ingelheim , KG Nippon Boehringer (Allergy, Biotechnology) (Immunology, Inflammation, Cardiovascular) (Virology) BI Canada (Oncology) (Respiratory, CNS, Metabolic Diseases)
  • BIC Companies - 6,000 employees Roxane Laboratories, Inc. Columbus, OH Boehringer Ingelheim Corporation Boehringer Ingelheim Pharmaceuticals, Inc. BI Services Center, Inc. Boehringer Ingelheim Cares Foundation, Inc. Ridgefield, CT 2,300 employees BI Vetmedica St. Joseph, MO Boehringer Ingelheim Chemicals, Inc. Petersburg, VA Ben Venue Labs Bedford, OH
  • US Statistics (2005 Projected)
    • Net Sales $ 4.2 billion +31%
    • Employees in US 6,000
    • Employees in Danbury/Ridgefield 2,300 +14%
    • Expected employee growth in CT 750
    • (over next seven years)
  • Products in the US
    • Brand Prescription Medicines
      • Chronic Obstructive SPIRIVA , COMBIVENT, ATROVENT
      • Pulmonary Disease
      • Urology FLOMAX
      • Virology (HIV/AIDS) VIRAMUNE, APTIVUS
      • Cardiology MICARDIS, AGGRENOX, CATAPRES
      • Immunology MOBIC
      • Neurology MIRAPEX
    • Generic Prescription Medicines
        • Over 200 products with specialties in anti–cancer, sterile injectables and sterile respiratory therapies
    • Over-the-Counter
        • DULCOLAX
  • Assisting the Community
    • Local
    • National
  • BI Cares Foundation
    • The Foundation’s mission is to improve lives through innovative philanthropic contributions and donations of healthcare products and resources.
      • BI Cares Foundation Patient Assistance Plan.
      • Hurricane Katrina assistance.
      • Product Donation Program.
  • Community Involvement - CT
    • Lung Health Screening Program
    • United Way of Northern Fairfield County
    • Regional Hospice of Western Connecticut
    • American Red Cross
    • Connecticut PBS – Family Science Expo
    • Abilities Beyond Disabilities (DATAHR)
    • Connecticut United for Research Excellence
    • Ives Center for the Arts
    • Girl Scout Council of SW Connecticut
    • Regional YMCA Center for Arts & Humanities
    • Special Olympics – Connecticut
    • Western Connecticut State University
  • Growth for the Future
  • Ridgefield campus projects
    • Lead Discovery Technologies Building dedicated in 2001
    • Kilo Lab
      • Completed in 2005, produces drug substances up to 5 kg quantities for research purposes.
    • On-site Child Care Center; September 2006
      • 19,000 sq ft stand alone building with a capacity for 256 infants, toddlers and preschoolers.
    • Physical Sciences building; March 2007
      • 86,000 sq ft building to accommodate relocation of our cardiovascular diseases research program from Germany.
      • 3 floors, 119 work stations for scientists and management.
  • Needs for the future
    • Educated workforce
    • Vibrant biopharmaceutical industry in CT
    • Public private sector collaborations
      • Clinical trials centers of excellence
      • IRB networks
  • Threats
    • Prescription drug importation
        • AKA price controls
    • Promotion restrictions
        • Inability to generate interest in new products
    • Access restrictions
        • Inability to gain market share
    • Increased costs of doing business
        • Energy, taxes, fees, liability
  • Web information
    • http://www.boehringer-ingelheim.com Worldwide web
    • http://us.boehringer-ingelheim.com US company web
    • https://www.pparx.org/Intro.php Partnership for Prescription Assistance
    • http://us.boehringer-ingelheim.com/about/philanthropy/Patient_Assistance_Program.html BI Cares Foundation Patient Assistance web